{"id":743780,"date":"2013-07-29T16:01:00","date_gmt":"2013-07-29T16:01:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/"},"modified":"2023-03-22T00:04:35","modified_gmt":"2023-03-22T04:04:35","slug":"merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/","title":{"rendered":"Merck Applauds Colombia for First PAHO\/WHO Verification of Elimination of River Blindness"},"content":{"rendered":"<p class=\"bwalignc\">       Historic Milestone Reflects Successful Collaboration Among MECTIZAN<sup>\u00ae<\/sup>        Donation Program and Partners     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      applauds the government of Colombia whose work with the MECTIZAN<sup><b>\u00ae<\/b><\/sup><br \/>\n      Donation Program and The Carter Center-sponsored Onchocerciasis<br \/>\n      Elimination Program for the Americas led to today\u2019s Pan American Health<br \/>\n      Organization, the World Health Organization\u2019s Regional Office for the<br \/>\n      Americas (PAHO\/WHO), verification of Colombia as the first country in<br \/>\n      the world to eliminate the transmission of river blindness<br \/>\n      (onchocerciasis), using MECTIZAN (ivermectin). Onchocerciasis is one of<br \/>\n      the leading causes of preventable blindness worldwide.\n    <\/p>\n<p>\n      \u201cWe are humbled by the great work of the MECTIZAN Donation Program and<br \/>\n      its partners in protecting future generations of Colombians from a<br \/>\n      disease that carries devastating implications for people, families,<br \/>\n      healthcare systems and local economies,\u201d said Kenneth C. Frazier,<br \/>\n      chairman and chief executive officer, Merck. \u201cIt is tremendously<br \/>\n      rewarding to see the alliance of partners achieve the long-held goal of<br \/>\n      making river blindness a disease of the past in Colombia.\u201d\n    <\/p>\n<p>\n      For more information, please view the news releases from:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.minsalud.gov.co%2FPaginas%2Feliminar-Oncocercosis.aspx&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=Colombia+Ministry+of+Health+and+Social+Protection+%28Spanish%29&amp;index=1&amp;md5=0f0e0bcf9c392a63ad3839579152f9a6\">Colombia<br \/>\n        Ministry of Health and Social Protection (Spanish)<\/a>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mectizan.org%2Fnews%2Fmdp-congratulates-colombia-for-achieving-verification-of-elimination-of-river-blindness%23main-content&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=MECTIZAN+Donation+Program&amp;index=2&amp;md5=805da9a9a5334163fe8e569fc3d80242\">MECTIZAN<br \/>\n        Donation Program<\/a>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cartercenter.org%2Fnews%2Fpr%2Fcolombia_072913.html&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=Carter+Center-sponsored+Onchocerciasis+Elimination+Program+for+the+Americas&amp;index=3&amp;md5=8a7004e8da640c63764281e0145d9fb4\">Carter<br \/>\n        Center-sponsored Onchocerciasis Elimination Program for the Americas<\/a>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.paho.org%2Fhq%2Findex.php%3Foption%3Dcom_content%26view%3Darticle%26id%3D8912%253Acolombia-is-first-country-in-the-world-to-eliminate-river-blindness%26catid%3D740%253Anews-press-releases%26Itemid%3D1926%26lang%3Den&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=PAHO%2FWHO&amp;index=4&amp;md5=1ca5f183eb25ee123a0d508a46e40e94\">PAHO\/WHO<\/a>\n      <\/li>\n<\/ul>\n<p>\n      <b>About the MECTIZAN Donation Program<\/b>\n    <\/p>\n<p>\n      In October 1987, Merck announced it would donate the medication MECTIZAN<br \/>\n      to all who need it for as long as necessary until onchocerciasis is<br \/>\n      eliminated as a public health problem. The MECTIZAN Donation Program<br \/>\n      reaches more than 100 million people annually. <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mectizan.org&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=www.mectizan.org&amp;index=5&amp;md5=f0f2e4853d082dcbff380ebbb0915e81\">www.mectizan.org<\/a>.\n    <\/p>\n<p>\n      In Latin America, since 1989, more than 10 million treatments of donated<br \/>\n      MECTIZAN have been delivered by community health workers and<br \/>\n      non-governmental organizations.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=6&amp;md5=6f84c049ed91ba9382deacd4422f5a15\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=Twitter&amp;index=7&amp;md5=48c610ba94153bb08cd73dba61cc1c8d\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=286b3a3009339f5c9958a0ae7c3ee6b8\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=YouTube&amp;index=9&amp;md5=4c6ced47bf4d4ba4e3f6fa532a69df3d\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50680094&amp;newsitemid=20130729006424&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=62247a1739c7ff40c4c6fef8a93d22ed\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Lainie Keller, 908-423-4187     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Historic Milestone Reflects Successful Collaboration Among MECTIZAN \u00ae Donation Program and Partners Merck (NYSE: MRK), known as MSD outside the United States and Canada, applauds the government of Colombia whose work with the MECTIZAN\u00ae Donation Program and The Carter Center-sponsored Onchocerciasis Elimination Program for the Americas led to today\u2019s Pan American Health Organization, the World Health Organization\u2019s Regional Office for the Americas (PAHO\/WHO), verification of Colombia as the first country in the world to eliminate the transmission of river blindness (onchocerciasis), using MECTIZAN (ivermectin). Onchocerciasis is one of the leading causes of preventable blindness worldwide. \u201cWe are humbled by the great work of the MECTIZAN Donation Program and its partners in protecting future generations of Colombians from a disease that carries devastating implications for people, families, healthcare systems and local economies,\u201d said Kenneth C. Frazier, chairman and chief executive<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,54,64,289],"class_list":["post-743780","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-corporate-responsibility-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Applauds Colombia for First PAHO\/WHO Verification of Elimination of River Blindness - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Applauds Colombia for First PAHO\/WHO Verification of Elimination of River Blindness - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Historic Milestone Reflects Successful Collaboration Among MECTIZAN \u00ae Donation Program and Partners Merck (NYSE: MRK), known as MSD outside the United States and Canada, applauds the government of Colombia whose work with the MECTIZAN\u00ae Donation Program and The Carter Center-sponsored Onchocerciasis Elimination Program for the Americas led to today\u2019s Pan American Health Organization, the World Health Organization\u2019s Regional Office for the Americas (PAHO\/WHO), verification of Colombia as the first country in the world to eliminate the transmission of river blindness (onchocerciasis), using MECTIZAN (ivermectin). Onchocerciasis is one of the leading causes of preventable blindness worldwide. \u201cWe are humbled by the great work of the MECTIZAN Donation Program and its partners in protecting future generations of Colombians from a disease that carries devastating implications for people, families, healthcare systems and local economies,\u201d said Kenneth C. Frazier, chairman and chief executive\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:35+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\\\/\",\"name\":\"Merck Applauds Colombia for First PAHO\\\/WHO Verification of Elimination of River Blindness - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2013-07-29T16:01:00+00:00\",\"dateModified\":\"2023-03-22T04:04:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Applauds Colombia for First PAHO\\\/WHO Verification of Elimination of River Blindness\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Applauds Colombia for First PAHO\/WHO Verification of Elimination of River Blindness - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/","og_locale":"en_US","og_type":"article","og_title":"Merck Applauds Colombia for First PAHO\/WHO Verification of Elimination of River Blindness - Merck.com","og_description":"Historic Milestone Reflects Successful Collaboration Among MECTIZAN \u00ae Donation Program and Partners Merck (NYSE: MRK), known as MSD outside the United States and Canada, applauds the government of Colombia whose work with the MECTIZAN\u00ae Donation Program and The Carter Center-sponsored Onchocerciasis Elimination Program for the Americas led to today\u2019s Pan American Health Organization, the World Health Organization\u2019s Regional Office for the Americas (PAHO\/WHO), verification of Colombia as the first country in the world to eliminate the transmission of river blindness (onchocerciasis), using MECTIZAN (ivermectin). Onchocerciasis is one of the leading causes of preventable blindness worldwide. \u201cWe are humbled by the great work of the MECTIZAN Donation Program and its partners in protecting future generations of Colombians from a disease that carries devastating implications for people, families, healthcare systems and local economies,\u201d said Kenneth C. Frazier, chairman and chief executive","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:35+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/","name":"Merck Applauds Colombia for First PAHO\/WHO Verification of Elimination of River Blindness - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2013-07-29T16:01:00+00:00","dateModified":"2023-03-22T04:04:35+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130729006424r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-applauds-colombia-for-first-paho-who-verification-of-elimination-of-river-blindness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Applauds Colombia for First PAHO\/WHO Verification of Elimination of River Blindness"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"6e41ce9f-5a0e-456f-ad79-f6a1db2b0473","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Applauds-Colombia-for-First-PAHOWHO-Verification-of-Elimination-of-River-Blindness-2013.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743780\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743780"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}